Healthequity Inc (NASDAQ:HQY) CEO Buys $610,000.00 in Stock

Healthequity Inc (NASDAQ:HQY) CEO Jon Kessler purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The shares were purchased at an average price of $61.00 per share, for a total transaction of $610,000.00. Following the transaction, the chief executive officer now owns 442,410 shares of the company’s stock, valued at approximately $26,987,010. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

HQY opened at $75.36 on Thursday. The company has a current ratio of 15.60, a quick ratio of 15.59 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $4.41 billion, a P/E ratio of 79.33, a price-to-earnings-growth ratio of 3.50 and a beta of 1.45. Healthequity Inc has a 52-week low of $50.29 and a 52-week high of $101.58. The firm’s fifty day moving average is $67.13.

Healthequity (NASDAQ:HQY) last posted its quarterly earnings data on Tuesday, June 4th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.11. The business had revenue of $87.05 million for the quarter, compared to the consensus estimate of $83.98 million. Healthequity had a net margin of 30.60% and a return on equity of 14.17%. As a group, sell-side analysts expect that Healthequity Inc will post 1.01 earnings per share for the current fiscal year.

Several analysts recently commented on HQY shares. JPMorgan Chase & Co. set a $69.00 price target on shares of Helmerich & Payne and gave the company a “buy” rating in a research report on Wednesday, June 5th. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. Zacks Investment Research lowered shares of HENGAN INTL GRP/ADR from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Bank of America set a $4.00 price target on shares of GameStop and gave the company a “sell” rating in a research report on Wednesday, June 5th. Finally, ValuEngine lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $86.25.

Institutional investors and hedge funds have recently bought and sold shares of the business. Manchester Capital Management LLC purchased a new position in shares of Healthequity in the first quarter worth about $36,000. Global Retirement Partners LLC lifted its stake in shares of Healthequity by 72.7% in the first quarter. Global Retirement Partners LLC now owns 556 shares of the company’s stock worth $41,000 after buying an additional 234 shares in the last quarter. Financial Gravity Wealth Inc. purchased a new position in shares of Healthequity in the first quarter worth about $45,000. Quantamental Technologies LLC lifted its stake in shares of Healthequity by 5,683.3% in the first quarter. Quantamental Technologies LLC now owns 694 shares of the company’s stock worth $51,000 after buying an additional 682 shares in the last quarter. Finally, Signaturefd LLC lifted its stake in shares of Healthequity by 24.3% in the first quarter. Signaturefd LLC now owns 803 shares of the company’s stock worth $59,000 after buying an additional 157 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About Healthequity

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Story: What is the Rule of 72?

Insider Buying and Selling by Quarter for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.